Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 39

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 39
---
 by the form of Series B-2 Common Warrant, which will be filed with the SEC as an exhibit to a Current Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants.

#### Duration and Exercise Price.
The Series B-2 Common Warrants offered hereby will have an exercise price of $1.30 per share (the assumed combined offering price per share of Common Stock and accompanying Common Warrants (the closing price of our Common Stock on Nasdaq on April 23, 2025)). The Series B-2 Common Warrants are exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the Series B-2 Common Warrants will be exercisable on the

<div align='center'>24</div>

Initial Exercise Date, at an assumed exercise price equal to $1.30 (equal to the assumed combined public offering price per share of Common Stock and accompanying Common Warrants). The Series B-2 Common Warrants will expire eighteen months from the Initial Exercise Date or the Warrant Stockholder Approval. The exercise price and number of shares of Common Stock issuable upon exercise of the Series B-2 Common Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock.

#### Exercisability.
The Series B-2 Common Warrants will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the Series B-2 Common Warrants will be exercisable on the Initial Exercise Date , at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).

#### Exercise Limitations.
We may not effect the exercise of any Series B-2 Common Warrants, and a holder will not be entitled to exercise any portion of any Series B-2 Common Warrants that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially